1500 related articles for article (PubMed ID: 23950185)
1. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
[TBL] [Abstract][Full Text] [Related]
2. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
Ciubotariu E; Gabay C; Finckh A;
J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
[TBL] [Abstract][Full Text] [Related]
3. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort.
Combe B; Logeart I; Belkacemi MC; Dadoun S; Schaeverbeke T; Daurès JP; Dougados M
Ann Rheum Dis; 2015 Apr; 74(4):724-9. PubMed ID: 24399234
[TBL] [Abstract][Full Text] [Related]
5. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
[TBL] [Abstract][Full Text] [Related]
6. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
[TBL] [Abstract][Full Text] [Related]
7. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
Rannio T; Asikainen J; Kokko A; Hannonen P; Sokka T
J Rheumatol; 2016 Apr; 43(4):699-706. PubMed ID: 26879355
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study.
Lutf A; Poil AR; Hammoudeh M
Int J Rheum Dis; 2014 Jan; 17(1):63-5. PubMed ID: 24472269
[TBL] [Abstract][Full Text] [Related]
9. Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.
Shu J; Bykerk VP; Boire G; Haraoui B; Hitchon C; Thorne JC; Tin D; Keystone EC; Pope JE;
J Rheumatol; 2015 Nov; 42(11):2023-8. PubMed ID: 26329342
[TBL] [Abstract][Full Text] [Related]
10. Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression.
Ellingsen T; Hansen I; Thorsen J; Møller BK; Tarp U; Lottenburger T; Andersen LS; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen A; Lindegaard H; Jacobsen S; Østergaard M; Vestergaard A; Jurik AG; Junker P; Christensen AF; Hetland ML; Hørslev-Petersen K; Stengaard-Pedersen K
Scand J Rheumatol; 2014; 43(2):91-100. PubMed ID: 23980529
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Radiographic Outcomes in Patients Diagnosed with Early Rheumatoid Arthritis in the First Years of the Biologic Treatment Era: A 10-year Prospective Observational Study.
Haugeberg G; Bøyesen P; Helgetveit K; Prøven A
J Rheumatol; 2015 Dec; 42(12):2279-87. PubMed ID: 26568592
[TBL] [Abstract][Full Text] [Related]
12. Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort.
Gaujoux-Viala C; Rincheval N; Dougados M; Combe B; Fautrel B
Ann Rheum Dis; 2017 Dec; 76(12):2054-2060. PubMed ID: 28866645
[TBL] [Abstract][Full Text] [Related]
13. Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort.
Combe B; Rincheval N; Berenbaum F; Boumier P; Cantagrel A; Dieude P; Dougados M; Fautrel B; Flipo RM; Goupille P; Mariette X; Saraux A; Schaeverbeke T; Sibilia J; Vittecoq O; Daurès JP
Rheumatology (Oxford); 2021 Nov; 60(11):5073-5079. PubMed ID: 33961011
[TBL] [Abstract][Full Text] [Related]
14. Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes.
Ruyssen-Witrand A; Guernec G; Nigon D; Tobon G; Jamard B; Rat AC; Vittecoq O; Cantagrel A; Constantin A
Ann Rheum Dis; 2015 Sep; 74(9):1676-83. PubMed ID: 24794151
[TBL] [Abstract][Full Text] [Related]
15. Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort.
Fautrel B; Granger B; Combe B; Saraux A; Guillemin F; Le Loet X
Arthritis Res Ther; 2012 Nov; 14(6):R249. PubMed ID: 23164197
[TBL] [Abstract][Full Text] [Related]
16. Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomized clinical NEO-RACo trial.
Rantalaiho V; Kautiainen H; Järvenpää S; Korpela M; Malmi T; Hannonen P; Kaipiainen-Seppänen O; Yli-Kerttula T; Möttönen T; Mustila A; Karjalainen A; Paimela L; Uutela T; Leirisalo-Repo M;
J Rheumatol; 2014 Dec; 41(12):2379-85. PubMed ID: 25274892
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort.
Khanna D; Oh M; Furst DE; Ranganath V; Gold RH; Sharp JT; Park GS; Keystone EC; Paulus HE;
Arthritis Rheum; 2007 Apr; 57(3):440-7. PubMed ID: 17394230
[TBL] [Abstract][Full Text] [Related]
18. Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions.
Castrejón I; Dougados M; Combe B; Fautrel B; Guillemin F; Pincus T
J Rheumatol; 2016 Jul; 43(7):1285-91. PubMed ID: 27084913
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
[TBL] [Abstract][Full Text] [Related]
20. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.
Dale J; Stirling A; Zhang R; Purves D; Foley J; Sambrook M; Conaghan PG; van der Heijde D; McConnachie A; McInnes IB; Porter D
Ann Rheum Dis; 2016 Jun; 75(6):1043-50. PubMed ID: 27026689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
